Leading Domestic Experts Work Routinely, Writing a New Chapter in Heavy Ion Development

— Professor Zhao Ren, Director of the Radiotherapy Department at Ningxia Medical University General Hospital,

provides routine guidance at the Wuwei Heavy Ion Center

On December 18, Professor Zhao Ren, Director of the Radiotherapy Department at Ningxia Medical University General Hospital, visited the Wuwei Heavy Ion Center. He conducted in-depth professional rounds in radiotherapy-related wards, participated in discussions on complex cases, and provided on-site guidance on the application of cutting-edge technologies. His visit brought extensive academic expertise and professional insights to the center.

Professor Zhao Ren, a senior expert in radiotherapy and chief physician, holds multiple key positions:  

- Standing Committee Member of the Radiotherapy Oncology Committee of the Chinese Medical Association  

- Committee Member of the Lung Cancer Committee of the Chinese Anti-Cancer Association  

- Committee Member of the Targeted Therapy Committee of the Chinese Anti-Cancer Association  

- Committee Member of the Esophageal Cancer Group of the Nutrition and Supportive Therapy Committee of the Chinese Anti-Cancer Association  

- Chairman of the Lung Cancer Committee of the Ningxia Anti-Cancer Association  

- Director of the Ningxia Clinical Medical Research Center for Malignant Tumors  

- Vice Chairman of the Esophageal Cancer Committee of the Ningxia Anti-Cancer Association  

He specializes in the comprehensive clinical and research management of thoracic tumors (including lung cancer, esophageal cancer, mediastinal tumors, etc.), with expertise in radiotherapy, chemotherapy, targeted therapy, and immunotherapy.

In recent years, Gansu Wuwei Cancer Hospital has achieved significant milestones in advancing the Heavy Ion Treatment Alliance and establishing 50 expert workstations. As the only hospital in the world operating two heavy-ion treatment systems simultaneously, Gansu Wuwei Cancer Hospital remains steadfastly committed to the continuous development and innovation of cancer treatment technologies. Since the Wuwei Heavy Ion Center officially began clinical operations in March 2020, it has successfully treated over 2,400 patients, delivering notable clinical outcomes. The range of treated conditions is extensive, covering more than 50 types of cancers, including lung cancer, pancreatic cancer, liver cancer, and glioma. Patients come from a diverse array of regions, spanning mainland China, Hong Kong, Macao, Taiwan, as well as countries such as Belgium, Australia, South Korea, Malaysia, Vietnam, and Singapore.

During ward rounds, Professor Zhao Ren personally visited the patient wards, inquiring in detail about each patient's condition and treatment progress. He engaged in in-depth discussions and exchanges with doctors from the radiotherapy-related departments. Based on the specific circumstances of each patient, the team provided precise and personalized treatment recommendations. Professor Zhao Ren particularly emphasized that cancer treatment is a highly comprehensive systemic process. It requires careful consideration of multiple factors, such as the patient's physical condition, tumor type, and stage, to formulate the most suitable treatment plan for each individual.

The routine work of Professor Zhao Ren is certain to powerfully propel the disciplinary development and clinical capabilities of the Wuwei Heavy Ion Center to new heights. Looking ahead, Gansu Wuwei Cancer Hospital will continue to deepen the construction of the Heavy Ion Treatment Alliance, steadily advance the work of the 50 expert workstations, and comprehensively enhance the hospital's overall capabilities. Under the joint leadership of esteemed experts such as Zhao Ren, Yu Zhilong, Lan Shengmin, Zhang Yingdong, Feng Qinfu, Ma Lulin, Ma Changying, and Fan Ruitai, the Wuwei Heavy Ion Center is poised to achieve even more outstanding results in the field of cancer treatment, bringing hope and illuminating the path forward for countless cancer patients.